EPISODE · Sep 27, 2026 · 25 MIN
Episode #128 | Biotools Can Beat Moonshots with Jim West
from The Lattice (Official 3DHEALS Podcast) · host 3DHEALS
Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded. Show notes YouTube Recording Send us Fan Mail Support the show Subscribe to our premium version and support the show. Follow us: Twitter Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D
Embed this episode
What this episode covers
Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still oper...
Ready to play
Episode #128 | Biotools Can Beat Moonshots with Jim West
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.